acly

MEDICA16 is a selective agonist for GPR40 as well as a partial agonist for GPR120. MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle with an increase in insulin sensitivity.

Itaconate-alkyne (ITalk) is a bioorthogonal probe for quantitative, site-specific chemoproteomic profiling of itaconate in inflammatory macrophages, facilitating biochemical evaluation and proteomic analysis of its direct targets.

Citric acid trilithium salt tetrahydrate (Lithium citrate tribasic tetrahydrate) , the active component of Lithium, is a medicine used in the therapy of psychiatric disease. It has shown the effects of signaling pathways and metabolic in the brain based on the particular disease and clinical condition model. According to the reports, Citric acid trilithium salt tetrahydrate was used as a mood stabilizer when treating bipolar mood disorders (BD) and lower the risk of self-harm in BD patient. In addition,Citric acid trilithium salt tetrahydrate has been the choice drug in the therapy of acute manic episodes.Citric acid trilithium salt tetrahydrate also could dissolve uric acid crystals in urine achieved from patients with gout. Besides,Citric acid trilithium salt tetrahydrate have some dose-dependent side-effects. The the main side-effects of Lithium Citrate is the tendency to inhibit the prostatic acid phosphatase enzyme (PAP), which result in the accumulation of PAP.

Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) is the major active ingredient of Garcinia cambogia and a derivative of citric acid, which effectively inhibits stone formation and HIF, and has antioxidation, anti-inflammation, and anti-tumor effects. It also competitively inhibits ATP citrate lyase, offering weight loss benefits.

Bempedoic acid (ETC1002) is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid(ETC1002) is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid(ETC1002) is a regulator of lipid and carbohydrate metabolism.

2-Furoic acid (Furan-2-carboxylic acid) reduces serum cholesterol and triglyceride levels and exhibits anti-lipidemic effects.

(-)-Hydroxycitric acid (Garcinia acid) is the principal acid found in the fruit rinds of Garcinia cambogia. It acts as a potent and competitive inhibitor of ATP citrate lyase, suppressing fatty acid synthesis, food intake, lipogenesis, and inducing weight loss.

(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a potent inhibitor of ATP citrate lyase, an enzyme that catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA.

SB 204990 is a lactone prodrug of SB-201076, a potent and specific ATP citrate lyase inhibitor.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL).

NDI-091143 is a potent, high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), indirectly disrupting citrate binding via an unexpected mechanism of inhibition.

ACLY Inhibitor 7 is a highly potent and selective small molecule inhibitor that exhibits exceptional inhibitory activity against human ATP citrate lyase (hACLY). ACLY Inhibitor 7 demonstrates an IC50 value of less than 1 nM as measured by the ADP-Glo assay, indicating its potential for metabolic disease and oncology research.

ACLY-IN-1 (compound 55) is a potent ACLY inhibitor with an IC50 of 8.3 nM, and it can be utilized in hyperlipidemia research.

AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for anti-CXCR4 ADC, exhibiting potent antitumor activity and comprising the auristatin microtubule inhibitor Aur0101, connected through the cleavable linker AcLys-PABC-VC[1].

AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporating the natural bis-intercalator SW-163D through an AcLysValCit-PABC-DMAE linker[1].

MC-AcLys-GDEVD-PABC-Exatecan is a component of an antibody-drug conjugate (drug-linker conjugate for ADC) composed of an ADC linker (MC-AcLys-GDEVD-PABC) attached to the DNA topoisomerase I inhibitor, Exatecan. It operates by enhancing the release of small molecule drugs into the tumor microenvironment through a significant bystander effect, triggered by caspase-3-induced extracellular cleavage of the linker.

AcLys-PABC-VC-Aur0101 intermediate-1, a cathepsin-cleavable ADC linker, facilitates the production of antibody-drug conjugates [1].

Bendazac L-lysine (Bendazaco lisina) is an agent introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.

Flunisolide (Rhinalar) is a synthetic corticosteroid with anti-inflammatory and antiallergic properties.

Ac-Lys-AMC (Hexanamide) is a fluorescent substrate for histone deacetylase HDACs.

Alclofenac is an anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also used as an analgesic and an antipyretic.

Ac-Lys-OMe.HCl is an amino acid derivative and has a wide range of applications in life science related research.

Ac-Lys-Val-Cit-PABC-MMAE is a conjugate consisting of an antibody-drug conjugate (ADC) linker (peptide Ac-Lys-Val-Cit-PABC) and the cytotoxic agent monomethyl auristatin E (MMAE), a potent tubulin polymerization inhibitor [1].

Ac-Lys-Val-Cit-PABC-MMAE (formic) is an agent-linker conjugate used in antibody-drug conjugates (ADCs), consisting of a peptide linker (Ac-Lys-Val-Cit-PABC) attached to the cytotoxic agent Monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization[1].